Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AUTL NASDAQ:KRRO NASDAQ:MGNX NASDAQ:UPXI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUTLAutolus Therapeutics$1.73-2.0%$1.69$1.11▼$5.00$469.21M1.842.34 million shs25,876 shsKRROKorro Bio$46.41+1.3%$28.43$10.29▼$98.00$412.60M2.89138,702 shs2,044 shsMGNXMacroGenics$1.75+2.0%$1.67$0.99▼$5.10$113.46M1.61635,978 shs593,657 shsUPXIUpexi$7.01-2.3%$6.49$1.90▼$22.57$418.17M-0.534.04 million shs106,832 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUTLAutolus Therapeutics+18.12%+5.39%+23.08%-29.03%-56.65%KRROKorro Bio-6.07%+4.35%+39.16%+237.09%+30.85%MGNXMacroGenics+3.49%+4.71%+1.14%+12.66%-50.83%UPXIUpexi+1.70%+9.80%+26.68%+43.40%+173.66%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUTLAutolus Therapeutics$1.73-2.0%$1.69$1.11▼$5.00$469.21M1.842.34 million shs25,876 shsKRROKorro Bio$46.41+1.3%$28.43$10.29▼$98.00$412.60M2.89138,702 shs2,044 shsMGNXMacroGenics$1.75+2.0%$1.67$0.99▼$5.10$113.46M1.61635,978 shs593,657 shsUPXIUpexi$7.01-2.3%$6.49$1.90▼$22.57$418.17M-0.534.04 million shs106,832 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUTLAutolus Therapeutics+18.12%+5.39%+23.08%-29.03%-56.65%KRROKorro Bio-6.07%+4.35%+39.16%+237.09%+30.85%MGNXMacroGenics+3.49%+4.71%+1.14%+12.66%-50.83%UPXIUpexi+1.70%+9.80%+26.68%+43.40%+173.66%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUTLAutolus Therapeutics 2.71Moderate Buy$9.12428.70% UpsideKRROKorro Bio 3.00Buy$86.8387.10% UpsideMGNXMacroGenics 2.29Hold$3.60105.25% UpsideUPXIUpexi 2.67Moderate Buy$15.50121.27% UpsideCurrent Analyst Ratings BreakdownLatest MGNX, UPXI, KRRO, and AUTL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025AUTLAutolus TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025MGNXMacroGenicsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025AUTLAutolus TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025KRROKorro BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025MGNXMacroGenicsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025UPXIUpexiWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/24/2025AUTLAutolus TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform9/17/2025MGNXMacroGenicsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$3.009/16/2025MGNXMacroGenicsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/15/2025MGNXMacroGenicsLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$8.00 ➝ $5.008/13/2025AUTLAutolus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$6.00 ➝ $5.00(Data available from 10/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUTLAutolus Therapeutics$10.12M45.36N/AN/A$1.61 per share1.07KRROKorro Bio$2.27M191.98N/AN/A$17.12 per share2.71MGNXMacroGenics$163.87M0.68N/AN/A$1.85 per share0.95UPXIUpexi$15.81M26.09N/AN/A$1.01 per share6.94Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUTLAutolus Therapeutics-$220.66M-$0.84N/AN/AN/AN/A-56.18%-29.61%11/11/2025 (Estimated)KRROKorro Bio-$83.58M-$9.75N/AN/AN/AN/A-61.51%-42.87%11/11/2025 (Estimated)MGNXMacroGenics-$66.97M-$0.57N/AN/AN/A-21.99%-40.24%-14.62%11/4/2025 (Estimated)UPXIUpexi-$13.68MN/A0.00∞N/A-86.54%-54.33%-31.28%N/ALatest MGNX, UPXI, KRRO, and AUTL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/4/2025Q3 2025MGNXMacroGenics-$0.42N/AN/AN/A$28.72 millionN/A8/14/2025Q2 2025MGNXMacroGenics-$0.59-$0.57+$0.02-$0.57$28.06 million$22.24 million8/12/2025Q2 2025AUTLAutolus Therapeutics-$0.24-$0.18+$0.06-$0.18$12.92 million$13.50 million8/12/2025Q2 2025KRROKorro Bio-$2.54-$2.74-$0.20-$2.74$0.41 million$1.46 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAUTLAutolus TherapeuticsN/AN/AN/AN/AN/AKRROKorro BioN/AN/AN/AN/AN/AMGNXMacroGenicsN/AN/AN/AN/AN/AUPXIUpexiN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUTLAutolus TherapeuticsN/A8.438.07KRROKorro BioN/A5.985.98MGNXMacroGenicsN/A5.265.02UPXIUpexiN/A1.741.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUTLAutolus Therapeutics72.83%KRROKorro Bio13.18%MGNXMacroGenics96.89%UPXIUpexi5.68%Insider OwnershipCompanyInsider OwnershipAUTLAutolus Therapeutics25.70%KRROKorro Bio4.60%MGNXMacroGenics13.00%UPXIUpexi4.42%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUTLAutolus Therapeutics330266.14 million197.74 millionOptionableKRROKorro Bio709.39 million8.96 millionNo DataMGNXMacroGenics43063.21 million54.99 millionOptionableUPXIUpexi13058.89 million56.29 millionOptionableMGNX, UPXI, KRRO, and AUTL HeadlinesRecent News About These CompaniesUpexi to Participate in Upcoming October Investor ConferencesOctober 6 at 10:17 AM | markets.businessinsider.comUpexi, Inc. to Participate in Multiple Investor Conferences in October 2025October 6 at 8:31 AM | quiverquant.comQUpexi, Inc. (NASDAQ:UPXI) Sees Large Growth in Short InterestOctober 4, 2025 | marketbeat.comUpexi adds SOL Big Brain to advisory committeeSeptember 30, 2025 | msn.comUpexi Welcomes SOL Big Brain to the Upexi Advisory CommitteeSeptember 30, 2025 | markets.businessinsider.comKathmere Capital Management LLC Makes New Investment in Upexi, Inc. $UPXISeptember 27, 2025 | marketbeat.comUpexi (UPXI) Expected to Announce Earnings on MondaySeptember 25, 2025 | marketbeat.comUpexi Inc: Upexi Reports Financial Results for Fiscal Year Ended June 30, 2025 and Provides Shareholders with Solana Treasury Update Since June 30, 2025September 25, 2025 | finanznachrichten.deUpexi, Inc. Reports Financial Results for Fiscal Year 2025 and Provides Update on Solana Treasury PerformanceSeptember 24, 2025 | quiverquant.comQUpexi Reports Financial Results for Fiscal Year Ended June 30, 2025 and Provides Shareholders with Solana Treasury Update Since June 30, 2025September 24, 2025 | globenewswire.comUpexi, Inc. (NASDAQ:UPXI) Short Interest UpdateSeptember 15, 2025 | marketbeat.comUpexi Stock Pops Pre-Market, Retail Chatter Surges On Growing Solana Treasury HoldingsSeptember 12, 2025 | msn.comUpexi's Stellar Gains: Solana Treasury Strategy Drives 129% Growth in SOL ValueSeptember 12, 2025 | econotimes.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Upexi, Inc. (NASDAQ: UPXI)September 11, 2025 | prnewswire.comUpexi Adjusted SOL per Share Increases 129% Since Treasury LaunchSeptember 11, 2025 | globenewswire.comSolana gains 5% as Forward Industries reveals $1.6 billion SOL treasury planSeptember 8, 2025 | fxstreet.comUpexi Engages in September 2025 Investor ConferencesSeptember 8, 2025 | tipranks.comUpexi to Participate in Upcoming September ConferencesSeptember 3, 2025 | manilatimes.netMBitcoin Gains As ‘September Slump’ Remains Uncertain – Retail Traders Bet On Break From Trend In 2025September 3, 2025 | msn.comUpexi, Inc. Announces Strategic Investment in Alpha ExchangeAugust 28, 2025 | markets.businessinsider.comUpexi Invests in Alpha Exchange for Revenue ShareAugust 27, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMGNX, UPXI, KRRO, and AUTL Company DescriptionsAutolus Therapeutics NASDAQ:AUTL$1.72 -0.04 (-1.99%) As of 09:35 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.Korro Bio NASDAQ:KRRO$46.41 +0.60 (+1.31%) As of 09:34 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.MacroGenics NASDAQ:MGNX$1.75 +0.03 (+1.98%) As of 09:34 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.Upexi NASDAQ:UPXI$7.00 -0.17 (-2.30%) As of 09:35 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Upexi, Inc. manufactures and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc. and changed its name to Upexi, Inc. in August 2022. The company was incorporated in 2018 and is headquartered in Clearwater, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Rocket Lab: A Space Giant Hitting New Highs—Time to Chase? Why Archer Aviation Stock Is Soaring—And What Comes Next Lithium Americas: Why This 31% Rally Is More Than Just a Headline Energy Transfer's New Growth Engine Ignites Investor Interest AMD Could Double From Here—Thanks to Its Blockbuster OpenAI Deal AMD and OpenAI: A Partnership That Just Redrew the AI Map EA’s $55 Billion Deal Spurs a Shake-Up in the Gaming Sector 3 Dividend Aristocrats to Buy Before Year’s End Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
